CombiMatrix Q4 Revenues Grow 25 Percent, Loss Widens | GenomeWeb

The story has been updated to include comments from the company's earnings conference call.

NEW YORK (GenomeWeb News) – CombiMatrix today said that revenues in the fourth quarter rose 25 percent year over year as revenues from core prenatal testing markets spiked 161 percent.

For the three months ended December 31, 2012, the Irvine, Calif.-based firm saw revenues increase to $1.5 million from $1.2 million a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.